Cartesian Therapeutics (RNAC) Interest Coverage Ratio (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Interest Coverage Ratio of 22.67 for Q1 2026, up 67.17% year-over-year from 13.56 in Q1 2025, and up 67.28% quarter-over-quarter from 69.29 in Q4 2025.
Powered by 
Analysis
Cartesian Therapeutics (RNAC) Interest Coverage Ratio (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Interest Coverage Ratio for 12 consecutive years, with 22.67 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 67.17% year-over-year to 22.67; the TTM figure through Mar 2026 stood at 40.75 (down 10241.13% YoY), while the FY2025 annual figure was 0.48, down 172.72% from the prior year.
- Interest Coverage Ratio grew to 22.67 in Q1 2026 per RNAC's latest filing, from 69.29 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 19.38 in Q2 2022 and bottomed at 69.29 in Q4 2025.
- Historically, Interest Coverage Ratio has averaged 13.25 across 5 years, with a median of 4.14 in 2025.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio jumped 2949.22% — and 2024, when it sank 9394.14%.
- Cartesian Therapeutics' Interest Coverage Ratio stood at 5.19 in 2022, then jumped by 94.64% to 0.28 in 2023, then tumbled by 9394.14% to 26.44 in 2024, then slumped by 162.05% to 69.29 in 2025, then soared by 67.28% to 22.67 in 2026.
- Business Quant data shows RNAC's Interest Coverage Ratio at 22.67 in Q1 2026, 69.29 in Q4 2025, and 4.14 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Cartesian Therapeutics | 271.98 Mn | 271.98 Mn | - | -34.22 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -34.22 |
| Sep 30, 2023 | -10.26 |
| Jun 30, 2023 | -24.78 |
| Mar 31, 2023 | -22.75 |
| Dec 31, 2022 | -10.53 |
| Sep 30, 2022 | -1.99 |
| Jun 30, 2022 | 19.38 |
| Mar 31, 2022 | 15.24 |
| Dec 31, 2021 | 5.74 |
| Sep 30, 2021 | -2.77 |
| Jun 30, 2021 | 0.64 |
| Mar 31, 2021 | -10.07 |
| Dec 31, 2020 | -11.08 |
| Sep 30, 2020 | -37.63 |
| Jun 30, 2020 | -79.84 |
| Mar 31, 2020 | -68.95 |
| Dec 31, 2019 | -37.52 |
| Sep 30, 2019 | -30.40 |
| Jun 30, 2019 | -40.59 |
| Mar 31, 2019 | -29.94 |